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ABSTRACT 
Induction of humoral responses to HIV at mucosal compartments without 
inflammation is important for vaccine design. We developed charged wax 
nanoparticles that efficiently adsorb protein antigens and are internalized by DC in the 
absence of inflammation. HIV-gp140-adsorbed nanoparticles induced stronger in vitro 
T-cell proliferation responses than antigen alone. Such responses were greatly 
enhanced when antigen was co-adsorbed with TLR ligands. Immunogenicity studies 
in mice showed that intradermal vaccination with HIV-gp140 antigen-adsorbed 
nanoparticles induced high levels of specific IgG. Importantly, intranasal 
immunization with HIV-gp140- adsorbed nanoparticles greatly enhanced serum and 
vaginal IgG and IgA responses. Our results show that HIV-gp140-carrying wax 
nanoparticles can induce strong cellular/humoral immune responses without 
inflammation and may be of potential use as effective mucosal adjuvants for HIV 
vaccine candidates. 
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1. Introduction 
The HIV pandemic continues to be a major global health priority, and while 
there has been good progress in the development of antiretroviral drugs that have 
contributed to longer survival of infected individuals, prospects of an effective 
vaccine against HIV remain largely elusive [1;2]. Different strategies to induce 
effective immune responses to HIV have been attempted in both animal and human 
models but with little success and controversial results [3;4], although some protective 
responses have been reported [5;6]. A critical goal of HIV vaccination is the induction 
of mucosal humoral immune responses. This is predicated on the production of 
antibodies (Ab) with capacity of hindering the entrance of HIV and its subsequent 
interaction with target cells at mucosal sites either by viral neutralization, aggregation, 
or Fc receptor mediated mechanisms [7]. Because HIV antigens (Ag) alone induce 
very low if any immune responses, the use of adjuvants is of paramount importance. 
Adjuvants being molecules, compounds or macromolecular complexes that boost the 
potency and longevity of specific immune responses to Ag with little toxicity and 
long-lasting immune effects [8]. Biodegradable nanoparticles (NP, <700nm) have 
been studied extensively as vehicles for delivery of Ag to antigen presenting cells 
(APC) making them good adjuvant candidates [9-14]. NP can enhance the 
effectiveness of Ag uptake, which then increases Ag delivery to intracellular 
compartments of APC such as dendritic cells (DC) and macrophages [15]. Hence, NP 
may increase Ag presentation capacity, thus boosting cellular and humoral immune 
responses. 
The Ag delivery capacity of NP has been shown both in vitro and in vivo for a 
wide array of Ags such as tetanus toxoid [16], Neisseria meningitides [17], Bacillus 
anthracis [18], and HIV Ags [19-22]. These studies provide evidence that NP may be 
 4
an important tool for Ag delivery and subsequent induction of cellular and humoral 
immune responses, critical for development of vaccines. However, success in the 
development of NP as delivery systems of vaccines has been previously hampered by 
their low level of colloidal stability and wide limitations in manufacturing scale-up.   
We have developed NP made of yellow carnauba (YC) wax with high colloidal 
stability, low cost and scalable manufacture that would provide a rapid product 
development pathway. These YC-wax NP can efficiently adsorb Ags such as tetanus 
toxoid (TT) and the trimeric form of HIV Ag CN54-gp140 (gp140), and are readily 
internalized by APC with subsequent induction of cellular and humoral immune 
responses both in vitro and in vivo. In particular, Ag-adsorbed NP enhanced T-cell 
proliferation responses in human PBMC (TT) and mouse splenocytes (HIV gp140). 
Also, gp140-adsorbed NP greatly enhanced serum IgG and IgA after systemic 
immunization and, more importantly, induced high levels of vaginal IgG and IgA 
after intranasal immunization. 
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2. Materials and methods 
2.1 Particle production 
Solid lipid NP were prepared using a low pressure melt-emulsify-chill (MEC) 
process. A molten yellow carnauba (YC) wax (Koster Keunen, Watertown, CT) was 
dispersed into a hot aqueous emulsifier solution under control shear and then cooled 
to yield a stable dispersion of solid lipid NP. For the preparation of fluorescence NP, 
the oil-soluble fluorescent dye Pyrromethene-567A (emission wavelength 546nm, 
Exciton, Dayton, OH) was encapsulated in the NP. Cationic, anionic and non-ionic 
emulsifiers comprised of long carbon chains were used to stabilize and also modify 
the surface charge of the NP.  
Particle size was determined by photon correlation spectroscopy using a 
Brookhaven BI90 Plus (Brookhaven Instruments, Holtsville, NY). The zeta (Z) 
potential (a measure of the surface electrical charge) of the NP and Ags was measured 
in 1mM KCl by phase analysis light scattering using a Malvern Zetasizer NanoZS90 
(Malvern Instruments, Malvern, U.K.).  
Particle morphology was analyzed by electron microscopy. Serial dilutions of 
the NP in nanopure water were dispensed in 400nl drops onto a silicon chip, and left 
to dry. Samples were kept in the sputtering chamber at 5x102 mbar for about 4 hours, 
and then sputter-coated with 15nM gold. All images were taken at 25kV, and at 
various magnifications using a Hitachi S3500N scanning electron microscope. 
 
2.2. Antigens  
A clade C HIV-1 envelope clone p97CN54 was originally isolated from a 
Chinese patient [23] and was made available by H. Wolf and R. Wagner, University 
of Regensburg, Germany. Trimeric gp140 (gp120 plus the external domain (ED) of 
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gp140), designated CN54 gp140, was produced as a recombinant product in CHO 
cells and manufactured to GMP specification by Polymun Scientific, Vienna, Austria. 
Bovine serum albumin (BSA) and TT were obtained from Sigma-Aldrich, Ayrshire, 
UK and Statens Serum Institute, Denmark, Copenhagen, respectively.  
 
2.3. Antigen adsorption to nanoparticles 
Antigens were adsorbed to NP by means of electrostatic interaction after 
mixing 750µg of Ag in 1ml solution with 56.2µl of a 1% solids NP solution, and 
incubated at room temperature for 30min. To determine binding of Ag to the NP, the 
Z potential of NP was tested before and after protein adsorption, since proteins modify 
the NP surface charge. Adsorption was also tested by Bradford assay, and for gp140 a 
specific anti-gp140 ELISA was performed. Because the NP are made of wax material, 
it was not possible to spin down the NP for further testing of unbound Ag present in 
the supernatant, therefore a different protocol had to be used. After incubation of NP 
with Ag, the mix was spun at 4,000xg for 10min using a 1,000,000 MW cut-off 
Vivaspin filter (Sartorius Stedim Biotech, Goettingen, Germany). Antigen alone was 
spun in parallel to control for the amount of Ag retained in the filter. After 
centrifugation, the NP were retained in the filter and the amount of Ag present in the 
filtrate was then tested by Bradford and ELISA assays. To determine the amount of 
Ag adsorbed to NP, the amount of Ag detected in the colorimetric assays was 
calculated as a percentage of the amount of Ag alone recovered after filtration. 
Co-adsorption of Ag with the TLR-9 ligand CpGB or PolyI:C was performed 
using the YC-Brij700-chitosan NP, which are positively charged. CpGB (Eurofins 
MWG Operon, Ebersberg, Germany) and Poly (I:C) (Invivogen, San Diego, CA) was 
added to the NP-Ag complex at 4.25µg/ml final concentration and incubated for an 
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additional 30min. CpGB and Poly (I:C) binding was assessed using the PicoGreen 
dsDNA and RiboGreen dsRNA  quantitation reagents (Invitrogen Ltd, Paisley, UK). 
 
2.4. Isolation and culture of human dendritic cells 
Buffy coats obtained from healthy volunteers were used for separation of 
mononuclear cells (MNC) by density gradient centrifugation using ficoll-hypaque 
(Histopaque, Sigma). Monocytes were separated from non-adherent cells by 
adherence to plastic using complete medium (CM: RPMI-1640 plus 10mM HEPES, 
2mM L-glutamine, 100IU/ml penicillin, 100µg/ml streptomycin, all from Sigma) 
supplemented with 0.5% AB pooled human serum (PHS, Dynal Biotech, 
Ullernchausseen, Norway).  Adherent cells were then cultured for 4 days with 15ml 
CM supplemented with 5% PHS that contained 25ng/ml GM-CSF and 30ng/ml IL-4 
(R&D Systems, Inc, Minneapolis, MN). Complete medium with cytokines was 
replaced and after 3 days the cells were recovered and tested for cell morphology by 
optical microscopy, and for DC phenotype by immunofluorescence and flow 
cytometry. 
 
2.5. Optical microscopy 
Cells were placed in glass-bottom culture dishes (MatTek, Co, Ashland, MA) 
in CM plus GM-CSF and IL-4. The microscope and stage were enclosed within a 
heated (37°C) chamber (Solent Scientific,UK) and cells were cultured in 5% CO2 in 
air. Images were captured using an Olympus IX71 inverted fluorescence microscope 
equipped with a Hamamatsu C4742-95 digital camera, using a 20x objective with an 
additional 1.6x adaptor. Captured images were analyzed using Image Pro Plus 
software (Media Cybernetics, USA). 
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2.6. Immunofluorescence and flow cytometry 
Assessment of DC differentiation/enrichment and modulation of DC 
phenotype before and after treatment with gp140-adsorbed NP was determined by 
single cell surface immunostaining using monoclonal Abs against lineage markers and 
co-stimulatory molecules. Cells were stained with FITC-labeled anti–CD14, -CD3, -
CD19, -CD56, and -DC-SIGN; PE-labeled anti-CD11c, -CD40, -CD80, -CD83, –
CD86 and CCR7, and PE-Cy5-labeled-HLA-DR mAb. Ten thousand events were 
acquired in a FACSort Becton-Dickinson cytometer (San Jose, CA), and the samples 
were analyzed using the CellQuest software version 3.3 (Becton Dickinson, PaloAlto, 
CA). 
 
2.7. Nanoparticle cell internalization and intracellular tracking 
Nanoparticle-Ag cell internalization was tested by flow cytometry and 
confocal microscopy using Pyrromethene-567A-labeled NP. Cells (DC or THP-1 
cells) were cultured at 5x105/well in a 24-well plate with CM plus 5% PHS. 
Pyrromethen-567A-labeled Ag-adsorbed NP were added to the cells at a final dilution 
in CM corresponding to 5µg/ml gp140 and incubated overnight. 
For flow cytometry analysis, the cells were recovered after culture, were washed 
with PBS, and fixed with 1.5% formaldehyde. Ten thousand events were acquired and 
analyzed by flow cytometry as described above.  
For confocal analysis, DC were resuspended in 50ul of PBS containing 
5.0µg/ml red fluorescent Alexa Fluor-594 wheat germ agglutinin (WGA, Invitrogen) 
to stain the cell membrane. Cells were incubated for 10min at 37oC, then washed and 
fixed for 10min. After fixation, the fixing buffer was completely removed by 
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centrifugation, and the cells counterstained with Vectashield mounting medium 
(Vector Laboratories, Peterborough, UK) that contained DAPI. Cells were analyzed 
by confocal microscopy using a LSM 510 laser scanning microscope (Carl Zeiss 
MicroImaging, Germany). 
Tracking of NP-Ag within DC endolysosomes was assessed using a lysosome 
specific dye on DC cultured on Lab-tek chamber slides (Nalge Nunc International, 
Naperville, IL) pre-coated with gelatin. Dendritic cells were cultured overnight in CM 
containing IL-4 and GM-CSF. The CM was replaced with serum-free medium, and 
gp140-adsorbed NP at 5µg/ml Ag, final concentration were added to the wells 
together with 100µM Lysotracker Red (DND-99, Abs 577nm; Em 590nm, Invitrogen) 
prewarmed at 37oC in serum-free medium. The cells were incubated for 2h at 37oC 
after which the serum-free medium was replaced with CM, and analyzed by confocal 
microscopy. 
 
2.8. In vitro activation of human DC by antigen-adsorbed nanoparticles  
Differentiated immature DC were cultured in the presence of GM-CSF + IL-4, 
with or without gp140-adsorbed NP (5µg/ml final Ag concentration).  Modulation of 
DC activation/maturation was tested after 24, 48, and 72h by determining cell surface 
expression of CD40, CD54, CD80, CD83, CD86, CCR7, and HLA-class II using 
immunostaining and flow cytometry, and by assessing cytokine/chemokine release in 
the cell culture supernatants by multiplex assay. DC cultured in CM only were used as 
a negative control of stimulation, and in the presence of 25ng/ml TNF-α as a positive 
control. 
 
2.9. Cell proliferation assays 
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2.9.1. Human cells 
Human MNC (2x105 cells/200µl) were stimulated for 5 days with 12.5µg/ml 
TT in CM plus 5% PHS. Because nearly 100% of the TT was adsorbed to the NP (see 
section 3.1), an amount of 12.5µg/ml was used for both NP-adsorbed and free Ag. 
Free CpGB and Poly (I:C) were used at a final concentration of 4.25µg/ml, which was 
the same amount used for co-adsorption with Ag onto NP. Phytohaemaglutinin (PHA, 
5µg/ml, SIGMA) was used as a positive control of stimulation, and CM alone as a 
negative control. BSA-adsorbed NP, TT plus CpGB without NP, or chitosan alone 
were also used as controls. Cell proliferation was assessed by incorporation into DNA 
of [3H]Td (GE Healthcare, Buckinghamshire, UK). The cells were pulsed with 0.5µCi 
[3H]Td/well 18h before harvesting, and counts per minute (c.p.m.) determined in a 
liquid scintillation β counter (1450 Microbeta Plus, Wallac Oy, Turku, Finland). 
Proliferation response was calculated as the mean ± SD of the c.p.m. from three 
replicates. 
 
2.9.2. Murine cells 
Splenocytes from gp140-immune Balb/c mice were cultured for 3 days in the 
presence of 5µg/ml gp140, either free or adsorbed to NP. Concanavalin-A (5µg/ml, 
Sigma) was used as a positive control of stimulation. After 48h, the cells were pulsed 
as for human cells, and 18h later the cells were harvested and the c.p.m. counted. 
Proliferation response was expressed as stimulation index (PI), calculated by dividing 
the mean of the c.p.m. from three replicates of the experimental by the mean c.p.m. of 
the not-stimulated cells. 
 
2.10. ELISA  
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2.10.1. Detection of antigen-specific antibody responses 
Determination of specific TT serum IgG, specific gp140 serum IgG, IgG1, 
IgG2a, and IgA, as well as specific gp140 IgG and IgA in vaginal and nasal lavages, 
and in feces was performed by ELISA. ELISA plates (MaxiSorp, Nalge-Nunc 
International, Rochester, NY) were coated overnight at room temperature with 4µg/ml 
TT or 5µg/ml gp140 in PBS. Blocking was performed for 1h at 37oC with PBS 
containing 1% BSA. Serially diluted samples were incubated for 1h at 37oC. Bound 
IgG, IgG1, and IgG2a were detected by incubation for 1h at 37oC with goat anti-
mouse Ig-HRP (AbD Serotec, Kidlington, Oxford, UK), or with biotinylated goat 
anti-mouse IgA Ab (SouthernBiotech, Birmingham, AL) to detect bound IgA. An 
amplification step was performed to detect IgA by incubating the plates with HRP-
streptavidin conjugate (R&D Systems) for 1h at 37oC. Plates were developed by 
adding tetramethylbenzidine (TMB, Pierce-Endogen, Woburn, MA) and incubating 
the plates in the dark. The reaction was stopped using 1.0N H2SO4, and optical 
densities (O.D.) read at 450nm. A mix of pre-immune samples was run in 6-replicates 
per plate and the cut-off calculated (after subtracting the blank) as the mean of these 6 
values plus 3 SD, except for that of feces where 5 SD were used. 
 
2.10.2. Detection of gp140 
ELISA plates were coated with 1ug/ml in PBS of affinity purified sheep anti-
HIV-1-gp120 polyclonal antibody (AAlto Bio Reagents, Dublin, Ireland) and 
incubated overnight at room temperature. Blocking was performed for 1hour at 37oC 
with Buffer 1 (PBS plus 2% skimmed milk powder). gp140 standards and samples 
were added to the wells and incubated for 2h at 37oC. Detection of gp140 was 
performed by incubation for 1h at 37oC with 2µg/ml 5F3 anti-gp140 human mAb in 
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Buffer 2 (PBS supplemented with 2% skimmed powder milk, 5% porcine serum and 
0.5% Tween-20), followed by incubation for 1h at 37oC with goat anti-human IgG-
HRP (SouthernBiotech) in buffer 2. Plates were developed with TMB for 20min in 
the dark. The reaction was stopped with 1.0N H2SO4 and O.D. read at 450nm. 
 
2.11. Detection of cytokines/chemokines by multiplex assay 
Human cytokines/chemokines in cell culture supernatants were detected using 
an in-house multiplex assay following a protocol recommended by the manufacturers 
(R&D) as previously described [24]. 
 
2.12. In vivo immunizations with tetanus toxoid and gp140 
2.12.1. Animals 
 Female Balb/c mice, 6-8 week old, were obtained from Harlan Olac Ltd, UK. 
Mice were kept at the Biological Research Facility, St George’s University of 
London. All procedures were performed in accordance with the United Kingdom’s 
Home Office standards under the Animals Scientific Procedures Act, 1986, and 
approved by the School’s Ethical Review Committee.  
 
2.12.2. Immunization protocol and sample collection 
Mice were inoculated i.d. with 12.5µg (TT) or 20µg (gp140) in a total volume 
of 100µl in sterile saline on both dorsal flanks following a prime-boost-boost protocol 
at 4 (TT) and 3 (gp140) week intervals. For i.n. immunization, 20µg gp140 with or 
without NP in a maximum volume of 25µl were gently dispensed in the animal’s 
nostrils after isofluorane-induced anaesthesia. Antigen-adsorbed NP were prepared 
the same day of immunization. Alum-Ag complex was prepared by mixing equal 
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volumes of Ag and Alum solution (Imject Alum, Pierce, Rockford, IL), and mixed by 
rotation for 30 min at room temperature.  
Blood samples were collected before priming, 1-3 days before boosting, and at 4 
(TT) and 3 (gp140) weeks after the last boost. Serum was separated from clotted 
blood and stored at -80oC until further use. Vaginal samples were collected by 
flushing 30µl of PBS three times into the vagina of anaesthetized animals, pooled and 
supplemented with 8µl of a 25x protease inhibitor cocktail (Roche Diagnostics, 
Manheim, Germany). Samples were incubated for 30min on ice and then spun at 
14,000 rpm for 10min. Supernatants were collected and stored at -80oC. Eight fecal 
pellets/mouse were collected, weighed and mixed with 4x their weight of 1x protease 
inhibitor cocktail. Samples were homogenized to dissolve the pellets and incubated on 
ice for 1h. The samples were spun twice at 14,000rpm for 10min, and cleared 
supernatants stored at -80oC. Nasal samples were obtained after sacrifice of the 
animals by flushing the nasal cavity with 300µl of PBS containing 1x protease 
inhibitor cocktail. The samples were stored at -80oC.  
 
2.13. Statistical analyses 
Analyses were performed using GraphPad Prism, version 4.00 (GraphPad 
Software). Linear data was expressed as means ± SEM, whereas logarithmic data was 
expressed as geometric means ± 95% confidence interval. Statistical differences 
between groups were calculated using one-way ANOVA with Tukey’s multiple 
comparison posttest to compare groups by pairs. Differences between groups in 
relation to time were analyzed by two-way ANOVA with Bonferroni’s posttest for 
comparison of pairs. Paired Student’s t test was used to compare two groups. 
Differences were considered significant at P≤0.05.  
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3. Results 
3.1. Characterization of YC-wax nanoparticles 
Multiple types of YC-NP emulsified with different surfactants were screened 
for low cell toxicity, efficient cellular uptake, and good protein adsorption (data not 
shown). Three different YC-NP were selected that met these criteria: YC-SDS 
(yellow carnauba-sodium dodecil sulphate), YC-NaMA (sodium myristate acetate), 
and YC-Brij700-chitosan. The latter NP was emulsified with Brij700, a surfactant 
with a long carbon chain (C18) that contains 100 ethylenoxide (EO) units, and then 
mixed with medium molecular weight chitosan during the oil-in-water melting 
process to provide the NP surface with a positive charge. The NP were polydispersed 
with the following mean size (nm) and ZP (mV): YC-SDS, 306.7 and -47.7; YC-
NaMA, 454.3 and -64.1; and YC-Brij700-chitosan, 554.7 and +19.5. Measurements 
were performed in triplicate for two different batches of NP with variations between 
measurements of about 10%. Fig 1A shows a representative SEM picture of YC-SDS 
particles. Nanoparticles showed high stability at different temperatures in terms of 
particle size, ZP, sedimentation, and viscosity for up to 6 months after preparation 
(data not shown), demonstrating good colloidal stability. 
Zeta potential of the Ags, as expected, varied widely depending on the pH due 
to the amphoteric characteristics of the proteins. However, all three Ags (BSA, TT, 
and gp140) showed negative ZP at pH ranging between 7 and 8. Interestingly, 
whereas the ZP at this pH interval was about -10mV for BSA and gp140, that of TT 
reached -30mV. These results suggest that, at physiological pH, adsorption of Ags to 
the NP may vary depending on both NP and protein surface charge. However, all 
three Ags bound to anionic and cationic NP (data not shown and Fig 1B). Binding of 
gp140 to negatively (YC-SDS and YC-NaMA) and positively (YC-Brij700-chitosan) 
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charged NP is shown in Fig1B as indicated by the change in ZP of NP after 
incubation with gp140. We believe that association of these Ags with the YC-NP may 
be dominated by both electrostatic and hydrophobic interactions [25]. 
To further confirm adsorption of gp140 to NP, Bradford assay and gp140-
specific ELISA were also performed. Both assays showed that YC NP bound gp140 
with high efficiency (Fig 1C and D). It is noteworthy that binding for YC-NaMA NP 
appears higher by Bradford assay than by ELISA. However, because the latter 
assesses the antigenicity of gp140, masking of Ag epitopes after NP binding may 
account for this difference. Binding of BSA and TT to NP, assessed by Bradford, was 
also highly efficient (data not shown). 
 
3.2. YC-wax nanoparticles are internalized by antigen presenting cells 
In vitro human monocyte-derived DC were generated using a standardized 
protocol as described by Henderson, R.A., et al [26] with minor modifications. Blood-
derived monocytes were isolated by plastic adherence and showed typical spiky cell 
membrane projections following 7 days of culture in the presence of GM-CSF and IL-
4, as shown in Fig 2A. Immunostaining and flow cytometry analysis of 11 different 
DC isolations showed that 91.6% ± 3.8 (range: 84.7-96.6%) of cells had a DC 
phenotype with very low or negative expression of CD14, and high expression of 
CD11c, HLA-class II Ags, and DC-SIGN. CD40 and CD86 were consistently highly 
expressed on these cells, whereas CD80 and the maturation marker CD83 were 
expressed at low levels (Fig 2B). The non-DC present in these isolates were 
consistently B-lymphocytes (Fig. 2B inset). Both naked and TT- and gp140-adsorbed 
NP were readily internalized by DC as demonstrated by flow cytometry and confocal 
microscopy (Fig. 2C and D, respectively). Once internalized, NP were localized in 
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endolysosomes (Fig 2E). Cellular uptake of YC-wax NP was more efficient and was 
more uniformly distributed within the cell population than that of polystyrene 
nanobeads (Fig 2F). Here, 100% of THP-1 cells internalized YC-wax NP whereas 
about 70-90% of these cells internalized polystyrene NP. 
 
3.3. gp140-adsorbed YC-wax NP do not induce activation of DC neither by 
modulating cell surface activation/maturation markers nor release of 
cytokine/chemokines  
Human monocyte-derived DC were stimulated with gp140-adsorbed YC-wax 
NP (YC- SDS, YC-NaMA, and YC-Brij700-chitosan) and expression of the cell 
surface markers CD40, CD54, CD80, CD83, CD86, CCR7, and HLA-class II Ags 
was assessed by immunofluorescence and flow cytometry after 24, 48, and 72h post-
stimulation. There was no effect on the expression of these molecules, even when 
tested at an extended time point of 72h (data not shown). Likewise, there was no 
cytokine/chemokine induction by YC-wax-gp140-adsorbed NP (data not shown). 
Naked NP also did not induce any DC activation.  
 
3.4. YC-wax-nanoparticles enhance T-cell proliferation responses to antigen in 
human PBMC and mouse splenocytes 
We sought to determine whether YC-wax NP would enhance the T-cell 
proliferation responses to Ag. Since there are some limitations for the use of gp140 to 
induce human T-cell proliferation in vitro such as the lack of immune response in 
HIV unexposed healthy volunteers, and the anergic status of many HIV-infected 
individuals, TT was used as a model Ag. Hence, we tested the capacity of TT-
adsorbed YC-wax NP to enhance T-cell proliferation in fresh PBMC from healthy 
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volunteers. As shown in Fig. 3A, YC-wax NP enhanced T-cell proliferation to TT. 
This response was independent of the type of particles since both negatively (YC-wax 
SDS and YC-wax NaMA) and positively (YC-wax Brij700-chitosan) charged NP 
enhanced T-cell proliferation responses to TT (P<0.0001). This response was specific 
for TT as YC-wax NP adsorbed with the irrelevant Ag BSA did not induce T-cell 
proliferation (Fig. 3A). Interestingly, when the TLR-9 ligand CpGB (Fig 3B) but not 
the TLR-3 ligand Poly I:C (data not shown) was co-adsorbed with TT to YC-Brij700-
chitosan NP, the T-cell proliferation response was further enhanced (P<0.0001). To 
confirm that this effect was due to the co-adsorption of both TT Ag and CpGB to the 
YC-wax NP, several controls were performed (Fig 3B). Specifically, to test that the 
enhancing effect was not due to cell activation induced by the chitosan present on the 
YC-wax Brij700-chitosan NP, both chitosan alone and together with TT (in the 
absence of NP) were also assessed. Results show that neither chitosan nor 
TT+chitosan enhanced T-cell proliferation (Fig 3B). In addition, although CpGB 
induced T-cell proliferation on its own, this induction was significantly lower than 
that induced by TT-CpGB co-adsorbed NP. Further confirmation of the enhancing 
effect on T-cell proliferation by co-adsorption of TT plus CpGB on NP, was 
demonstrated when instead of using TT, the irrelevant Ag BSA was co-adsorbed to 
NP with CpGB (Fig 3B).  
To test whether NP could enhance T-cell proliferative responses to gp-140, 
splenocytes from gp140-immunized mice were used in vitro. Splenocytes were 
cultured in the presence of Ag alone or gp140-adsorbed NP and the incorporation of 
3H[Td] into DNA measured after three days of culture. gp140-adsorbed NP but not 
naked NP enhanced splenocyte proliferative responses to gp140 (P<0.001)(Fig 3C), 
indicating that such an effect was not due to the particles themselves. 
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3.5. YC-wax NP enhance systemic humoral immune responses to antigen in vivo 
Experiments were performed in mice using gp140-adsorbed NP to determine 
whether NP can enhance humoral responses to Ag in vivo. Similar experiments were 
performed previously using TT and results showed that systemic immunization with 
all three NP enhanced serum levels of specific anti-TT IgG after the first boost, which 
were comparable to those induced by Alum (Fig.4A). For induction of specific anti-
gp140 IgG and IgA, animals were immunized i.d. with gp140 following a prime-
boost-boost protocol at 30 day intervals. Serum samples were taken before each 
immunization and 30 days after the last boost, and the levels of IgG and IgA were 
tested by gp140-specific ELISA. gp140 alone induced significant levels of IgG but 
these levels were much higher when the Ag was adsorbed to NP (Fig 4B). Such IgG 
levels were comparable to or higher than those induced by Alum (day 60), and 
differences were already observable following a single prime (day 30).  Plateau IgG 
levels were already observed after first boost (day 60, Fig 4B). IgA anti-gp140 was 
only detected after second immunization but the levels were not high (maximum 
endpoint titers after second boost with Alum: 282.4 ± 88.4). Alum but not NP induced 
significantly higher IgA levels than those induced by Ag alone (first boost: P<0.001; 
second boost: P<0.05). The endpoint titers after second boost were: Ag alone: 78.5 ± 
26.5; YC-SDS-gp140: 137.0 ± 31.2; YC-NaMA-gp140: 238.5 ± 95.4; YC-Brij700-
chitosan-gp140: 243.8 ± 105.6; Alum-gp140: 282.4 ± 88.4.   
To test whether YC-wax NP modulated T-helper cell responses, the gp140 
specific IgG1/IgG2a ratio was also determined by ELISA. Of note, gp140 alone 
induced an IgG response that was biased towards a Th2 phenotype. Such a response 
did not appear to be modulated by Alum, YC-wax NaMA or YC-wax Brij700-
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chitosan (Fig 4C). However, YC-wax SDS appeared to induce a more balanced 
Th1/Th2 response (Fig.4C).  
 
3.6. YC-wax-nanoparticles enhance mucosal humoral responses to gp140 
To test whether NP were also capable of enhancing mucosal humoral 
responses to gp140, Mice were immunized nasally with either Ag alone or adsorbed 
to YC-wax-NaMA NP, and the levels of IgG and IgA were determined in serum and 
mucosal fluids. Antigen alone failed to induce any response (Fig 5). In contrast, there 
was a steady increase over time in both serum IgG and IgA in response to gp140 
adsorbed to YC-NaMA NP (Fig 5A). These levels did not seem to reach a plateau 
after the second boost, as it was observed with serum IgG after intradermal 
immunization. Notably, high levels of IgA were also observed in vaginal secretions, 
with a moderate increase in IgG (Fig 5B). In addition, IgG and IgA levels were also 
detected in the nasal lavages of these mice (Fig.5C). No antibody induction was 
observed in feces (data not shown). Of note, the IgG1/IgG2a ratio in serum was very 
close to 1 (1.57 +/- 0.079), which was lower than that induced by intradermal 
immunization with gp-140-YC-wax NaMA, suggesting that the type of T-helper 
immune response induced by NP may change depending on the route of 
immunization. 
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4. Discussion 
We have developed a highly stable NP vaccine delivery system made of YC-
wax material. These NP have a low cost of production that is easily scalable. Indeed, 
similar particles are already manufactured in kilogram quantities for use in the 
cosmetics industry. These features, together with their capacity to efficiently adsorb 
protein Ags, to be readily internalized by APC, and to enhance immune responses to 
Ag both in vitro and in vivo, make them good potential delivery systems for vaccines, 
and in particular that of HIV vaccines for the developing world.  
Manipulation of the YC-wax NP surface charge with surfactants, provides 
optimal flexibility to adsorb different types of Ag [27]. In this study, Ags as diverse as 
TT, BSA, and HIV-1 gp140 were efficiently adsorbed to both negatively and 
positively charged NP. In addition, the surface charge flexibility also facilitated co-
adsorption of more than one molecule onto the NP surface as shown by co-adsorption 
of Ag with CpGB and PolyI:C. After screening a large range of wax NP, three 
different types were selected according to their low toxicity, Ag adsorption efficiency, 
and cell internalization profile, i.e., YC-SDS, YC-NaMA, and YC-Brij700-chitosan. 
The first two NP had a net negative charge, whereas the third one was highly positive, 
a characteristic defined by the presence of the carbohydrate chitosan. We determined 
adsorption of gp140 to these NP by three different methods: Z potential, Bradford 
assay, and ELISA. All three methods provided strong evidence of effective Ag 
adsorption to NP. In addition, the ELISA assay suggested that antigenicity was 
unaffected, which may represent an advantage over Ag encapsulation as reported 
previously for a form of HIV-gp120 by Singh et al [28]. 
Flow cytometry and confocal microscopy studies clearly showed that Ag-
adsorbed YC NP were readily internalized by APC, and that these NP were 
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subsequently tracked within endolysosomes, suggesting that the NP may have the 
capacity to deliver Ag into the Ag processing and presentation compartment. 
Naked YC-wax NP did not induce cytokine/chemokine production or up-
regulation of co-stimulatory molecules on DC in vitro, nor induced visible signs of 
inflammation after both mucosal and systemic administration in vivo (data not 
shown). This lack of DC activation by naked NP is important especially if used at the 
urogenital tract, because such cell activation would induce mucosal inflammation at 
this level that may facilitate HIV infection.  
Antigen-adsorbed YC-wax NP (TT in human PBMC and gp140 in mouse 
splenocytes) enhanced T-cell proliferation responses in vitro. The response to TT by 
human PBMC was greatly enhanced by co-adsorption with CpGB (Fig 3B) but not 
with PolyI:C (data not shown). CpGB on its own enhanced cellular proliferation, and 
we speculate that CpGB induces non-specific proliferation of PBMC most likely due 
to polyclonal B cell activation, as has been described previously [29]. Nevertheless, 
the enhanced proliferation observed with co-adsorption of TT + CpGB particles was 
significantly greater than the additive effect of TT plus CpGB alone. 
Nanoparticles enhanced serum humoral immune responses to Ag in vivo. 
Animals immunized i.d. with gp140-adsorbed NP enhanced serum IgG production 
after a single prime, and this effect was comparable or better than that induced by 
Alum. Surprisingly, CpGB co-adsorbed to NP with either TT or gp140 did not 
enhance antibody production further (data not shown). Alum salts are well known 
strong parenteral adjuvants which are components of an array of licensed human 
vaccines [8]. However, to date they have not been successfully used for mucosal 
vaccination. Reactogenicity of Alum salts is an important characteristic of their 
adjuvanticity. Their mechanism of action has been associated with induction of local 
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uric acid crystals [30] and inflammasome activation with release of IL-1β by 
macrophages and DC [31;32]. Such reactogenicity is deemed too potent for mucosal 
use [33]. We do not know the mechanism of in vivo enhancement of humoral 
responses by gp140-adsorbed NP but since NP alone showed little if any 
reactogenicity in the skin of mice when compared to that induced by Alum, the 
mechanism of action may be highly different to that of Alum salts. The efficient cell 
internalization of NP and their subsequent localization within the endolysosome 
compartment in the absence of co-stimulatory molecule up-regulation and 
cytokine/chemokine production by DC clearly suggest a different mechanism. Thus, 
the lack of Alum-type reactogenicity of NP makes them good potential candidates for 
mucosal immunization. This may be particularly important where potential 
inflammation and edema have been associated with induction of Bell’s palsy [34]. 
We immunized mice with gp140-adsorbed YC-NaMA using different routes of 
immunization, including nasal, vaginal and rectal. The responses to gp140 via vaginal 
and rectal mucosal compartments were weak or null (data not shown). Reasons for 
this unresponsiveness in these mucosas may include physical properties of mucus 
(pore size and rheological factors) [35], and/or their paucity of follicle associated 
epithelium when compared to nasal associated lymphoid tissue (NALT). Nasal 
immunization, in contrast, potently induced both systemic and mucosal humoral 
immune responses. Intranasal immunization has been described as an effective route 
to induce systemic and mucosal immune responses to Ag, in particular in the 
urogenital tract, with scarce if any induction in the gut [36;37]. When mice were 
immunized nasally with gp140-adsorbed NaMA NP, high levels of IgG and IgA were 
induced in serum as well as vagina, and titers were still increasing following three 
immunizations. IgA levels in serum induced by i.n. immunization were around one to 
 23
two orders of magnitude higher than those induced by i.d. immunization. It is worth 
noting that levels of gp140-specific IgG and IgA were also enhanced in the nasal 
cavity. This suggests that wax NP may also have utility for delivering of immunogens 
against respiratory pathogens. M-cells of NALT are thought to play an important role 
in the uptake of NP in rodents and humans and are absent in vaginal and rectal 
mucosa [38-40]. 
The nasal route has been extensively studied not only for vaccination purposes 
[41-44] but also for the delivery of drugs [45], and NP have been used nasally to 
induce immune responses to TT [46] and HIV [47]. Induction of systemic and 
mucosal immune responses to HIV after nasal immunization of mice [48;49], guinea 
pigs [48] and macaques [5] with HIV-gp120 Ag has been described previously. In the 
latter, serum and vaginal Ab responses were induced after nasal immunization only 
when followed by one or two intramuscular boosts. These levels were highly 
enhanced in vagina after challenge with SHIV, suggesting that the nasal priming 
induced effective memory responses at mucosal level [5]. In our mouse model, three 
nasal immunizations were enough to induce high levels of IgG and IgA in serum and 
vagina. It remains to be confirmed whether this immunization protocol with NP will 
work similarly in macaques or humans, or whether these Abs would be neutralizing. 
Therefore, further studies are warranted that assess homologous and heterologous 
immunization protocols to determine the feasibility of using these NP, as effective 
delivery systems of HIV Ags, in the development of mucosal vaccination in humans.  
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Figure Legends 
 
Fig. 1. Physicochemical characterization of nanoparticles and binding to antigen. A, 
Scanning electron microscopy of YC-SDS NP. B, Zeta potential of naked NP and 
after adsorption with gp140 Ag. C, Attachment efficiency of gp140 to NP measured 
by Bradford assay. Numerical values on the Fig. are the percentage of Ag bound to 
NP after subtracting the amount detected on the filtrate of Ag alone. D, Detection by 
ELISA of gp140 adsorbed to NP. Values inside bars represent the percentage of Ag 
bound to NP with respect to Ag alone taken as 100%. 
Fig. 2. Analysis of gp140-adsorbed nanoparticle internalization by antigen presenting 
cells. A, Phase contrast microscopy of DC. B, Phenotype of in vitro differentiated 
human DC. Dot plot shows the gated DC population analyzed. Left histograms 
represent the isotype control. Inset depicts the staining for CD19+ showing about 10% 
of B cells. n represents the number of blood donors with the mean ± SD plus range of 
cells with a DC phenotype.  C, Flow cytometry analysis of gp140-adsorbed NP uptake 
by DC. Left histograms correspond to cells without NP. D, DC gp140-NP uptake as 
demonstrated by confocal microscopy. Red: cell membrane; Blue: Nucleus; Green: 
fluorescent NP. Values at the top left corner of each quadrant represent the distance in 
µm from top to bottom of the cell after every section. E, Lysosomal localization of 
gp140-NP within DC. Yellow color represents the overlapping of green (NP) plus red 
(lysosomes) colors. F, Comparison of NP uptake by THP-1 cells of two different 
types of NP: polystyrene (left) vs wax (right). Top right panel represents the MFI of 
cells without fluorescent NP. 
Fig. 3. Enhancement of T-cell proliferation responses to antigen after adsorption to 
nanoparticles. Human T-cell proliferation response to A, TT-adsorbed NP, and B, TT 
after co-adsorption to YC-Brij700-chitosan NP with CpGB. TT was used at 12.5 
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µg/ml and CpGB at 4.25µg/ml. Results shown are the mean ± SEM of c.p.m. values 
of three different donors performed in triplicate cultures. ***: P<0.001. C, Mouse 
splenocyte proliferation response to gp140-adsorbed NP. Splenocytes from gp-140 
immunized mice were stimulated in vitro with gp140-adsorbed NP at 5µg/ml final Ag 
concentration. Results shown are the mean ± SEM of the SI of two different 
experiments performed in triplicate. Mean comparisons were performed by one-way 
ANOVA. 
Fig. 4. In vivo humoral immune responses to antigen-adsorbed nanoparticles. Kinetics 
of serum IgG after i.d. immunization with A. TT and B. gp140. Groups of 8 mice 
were immunized three times with A. 12.5µg TT and B. 20µg gp140 either free or 
adsorbed to NP. Ag adsorbed to Alum was used as a positive control of immunization. 
Serum samples were obtained before each immunization and 30 days after the last 
immunization, and tested for IgG end-point titers by ELISA. Results shown are the 
mean ± SEM. Means were compared by two-way ANOVA. P values for TT: Ag 
alone vs YC-SDS-TT (60d): <0.001; vs YC-NaMA-TT (60d): <0.001, (90d): <0.05; 
vs YC-Brij700-chitosan-TT (60d): <0.01; vs Alum-TT (60d): <0.001. P values for 
gp140 at 60d: Ag alone vs: YC-SDS-gp140: P<0.001; vs YC-NaMA-gp140: P<0.05; 
vs YC-Brij700-chitosan-gp140: P<0.05; vs Alum-gp140: P<0.05. C, gp140-specific 
serum IgG1/IgG2a ratio. Serum samples obtained 30 days after the third 
immunization were tested by ELISA for gp140-specific IgG1 and IgG2a end-point 
titers. Plotted are the aggregated data of IgG1/IgG2a Log10 ratio values of two 
different experiments for the groups shown in the Fig. *: P<0.05; **: P<0.01; ***: 
P<0.001. 
Fig. 5. Systemic and mucosal humoral immune responses to gp140-adsorbed 
nanoparticles after intranasal immunization. A and B, Kinetics of serum and vaginal 
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IgG and IgA levels. Groups of 5 animals were immunized i.n. with 20µg of gp140 
either free or adsorbed to YC-NaMA NP. Serum and vaginal lavages were obtained 
before each immunization and 21 days after the last immunization, and tested for 
specific-gp140 IgG and IgA end-point titers by ELISA.  Means were compared by 
two-way ANOVA. ***: P<0.001. C, Levels of IgG and IgA in nasal lavage after 
second boost. Animals were immunized as in A and B, and 21 days after the last 
immunization the animals were sacrificed and the nasal cavity washed with saline. 
Samples were tested for gp140-specific IgG and IgA end-point titers as for A and B. 
Means were compared by paired t test. 
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